このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Acupuncture for Depression: Sigma-1 Receptor-Related Brain Network Modulation

2026年11月12日 更新者:Xinjing Yang、Shenzhen Hospital of Guangzhou University of Chinese Medicine

A Study on the Effects of Acupuncture in Treating Depression: Sigma-1 Receptor-Targeted pBFS for Individualized Brain Network Regulation and Prediction of Treatment Outcomes

This study will compare two types of acupuncture for adults with mild to moderate depression. One group will receive acupuncture. The other group will receive pivot acupuncture, a technique that uses needles at points on the head and neck. Participants with depression will be assigned to one of the two groups by chance. Both groups will attend three sessions a week for six weeks.

The researchers will compare how many people in each group have a substantial improvement in their depression symptoms by the end of treatment. They will also use brain scans and blood tests to examine whether symptom improvement is related to changes in how different parts of the brain work together and to changes in blood levels of a protein called the sigma-1 receptor.

調査の概要

状態

まだ募集していません

詳細な説明

In this parallel-group randomized trial, 72 adults with a mild to moderate depressive episode will be assigned in a 1:1 ratio to acupuncture or pivot acupuncture. The allocation sequence will be generated using SAS and concealed in sequentially numbered, opaque, sealed envelopes until treatment assignment.

Structural brain MRI, resting-state functional MRI, and peripheral blood sampling will be performed at baseline and at the end of the six-week treatment period. The personalized brain functional sectors (pBFS) method will be used to define 92 functional brain regions for each participant and estimate pairwise functional connectivity. The investigators will examine associations among changes in connectivity, peripheral sigma-1 receptor levels, and depressive symptoms. They will also explore whether changes in connectivity can estimate the magnitude of symptom improvement and compare models based on individualized and group-level brain maps.

研究の種類

介入

入学 (推定)

72

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~60年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Aged 18 to 60 years, inclusive.
  • Right-handed.
  • Diagnosed with a depressive episode according to ICD-10 code F32 and meeting DSM-5 criteria for a depressive episode.
  • Mild to moderate depressive symptoms, defined as a baseline score of at least 8 and less than 24 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
  • No use of immunomodulators, antidepressants, or other medications that affect mood in the month before enrollment.
  • Willing and able to follow study procedures and provide written informed consent.

Exclusion Criteria:

  • Another psychiatric disorder, such as bipolar disorder or schizophrenia.
  • Autoimmune disease or acute infection.
  • Intellectual disability (IQ below 70) or autism spectrum disorder.
  • History of epilepsy or a brain lesion.
  • History of drug dependence.
  • A contraindication to acupuncture, electroacupuncture, or MRI, such as an infectious condition that precludes needling, a history of fainting with needling, claustrophobia, or an MRI-incompatible intracranial implant.
  • Suicide risk identified at screening.
  • Current participation in another clinical trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Acupuncture

Participants will receive acupuncture three times a week for six weeks, for a total of 18 sessions. Each session will last 30 minutes.

The primary points are Baihui (GV20) and Yintang. Baihui is needled transversely from anterior to posterior to a depth of 0.5-0.8 cun. Yintang is needled slowly in a superior direction to a depth of 0.5-0.8 cun and gently rotated to de qi. Additional points are Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), Zusanli (ST36), and Taichong (LR3). Sterile acupuncture needles measuring 0.30 × 25 mm or 0.30 × 40 mm are used. Qualified practitioners with at least five years of clinical experience administer treatment.

アクティブコンパレータ:Pivot Acupuncture

Participants will receive pivot acupuncture three times a week for six weeks, for a total of 18 sessions. Needles will be retained for 20 minutes at each session.

Needles are placed at Fengfu (GV16), Naohu (GV17), and bilateral Fengchi (GB20), Tianzhu (BL10), Wangu (GB12), Yifeng (TE17), Tianyou (TE16), and Anmian. With participants supine, the skin is disinfected with 75% alcohol. Sterile, single-use Huanqiu needles (Suzhou Huanqiu Acupuncture Medical Appliance Co., Ltd., China), 0.30 × 25 mm or 0.30 × 40 mm, are inserted rapidly. Fengchi is needled obliquely toward the tip of the nose to a depth of 10-23 mm. Fengfu is needled straight toward the mandible to a depth of 10-23 mm. Naohu is needled obliquely downward to a depth of 23 mm. Tianzhu, Wangu, Yifeng, Tianyou, and Anmian are needled perpendicularly to a depth of 30 mm. Needles are manipulated by lifting, thrusting, and rotating, then retained for 20 minutes. Treatment is administered without electrical stimulation.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants With a Clinical Response on the HAMD-17
時間枠:Baseline and Week 6 (end of treatment).

Clinical response is defined as a reduction of at least 50% from baseline in the total score on the 17-item Hamilton Depression Rating Scale (HAMD-17). The HAMD-17 is a clinician-rated measure of depressive symptom severity. Total scores range from 0 to 52, with higher scores indicating more severe symptoms.

Baseline and Week 6 (end of treatment).

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants in Remission on the HAMD-17
時間枠:Week 6 (end of treatment).

Remission is defined as a total score below 8 on the 17-item Hamilton Depression Rating Scale (HAMD-17).

Week 6 (end of treatment).
Change From Baseline in HAMD-17 Total Score
時間枠:Baseline and Week 6 (end of treatment).

The Week 6 total score minus the baseline total score on the 17-item Hamilton Depression Rating Scale. Total scores range from 0 to 52, with higher scores indicating more severe symptoms. A negative change indicates improvement.

Baseline and Week 6 (end of treatment).
Change From Baseline in SF-12 Summary Score
時間枠:Baseline and Week 6 (end of treatment).

The 12-Item Short Form Health Survey (SF-12) is a self-reported measure of health status. Higher scores indicate better physical health. Change is calculated as the Week 6 score minus the baseline score.

Baseline and Week 6 (end of treatment).
Change From Baseline in BC-CCI-E Cognitive Complaints Score
時間枠:Baseline and Week 6 (end of treatment).

The British Columbia Cognitive Complaints Inventory-Expanded (BC-CCI-E) is a self-report measure of perceived cognitive difficulties. Higher cognitive complaints scores indicate more severe difficulties. Change is calculated as the Week 6 score minus the baseline score.

Baseline and Week 6 (end of treatment).
Suicide risk monitoring
時間枠:From enrollment through Week 10

Suicide risk will be assessed at baseline and weekly during the six-week treatment period using the Columbia-Suicide Severity Rating Scale (C-SSRS).

From enrollment through Week 10

その他の成果指標

結果測定
メジャーの説明
時間枠
Percentage of Participants With at Least One Adverse Event
時間枠:From enrollment through Week 10

Adverse events will be recorded from enrollment through the final follow-up visit. The number and percentage of randomized participants with at least one adverse event will be summarized by treatment group.

From enrollment through Week 10

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2028年1月1日

試験登録日

最初に提出

2026年11月12日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • NO.JCYJ20250604191311016

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する